Legal Proceedings Intensify: Class Action Filed Against MoonLake Immunotherapeutics by Robbins LLP

Legal Proceedings Intensify: Class Action Filed Against MoonLake Immunotherapeutics

A recent announcement from Robbins LLP has highlighted a significant legal development concerning MoonLake Immunotherapeutics (NASDAQ: MLTX), a Swiss biotechnology company focused on treating inflammatory diseases. On October 15, 2025, Robbins LLP informed stockholders that a class action lawsuit has been filed against MoonLake on behalf of all investors who acquired the company's common stock between March 10, 2024, and September 29, 2025.

MoonLake’s focus on inflammation particularly targets diseases linked to interleukin-17 (IL-17), which plays a crucial role in various dermatological and rheumatological conditions. However, recent performance-related disclosures have sparked serious concerns among investors, leading to speculation over the company's marketing practices and claims regarding its drug candidates.

Allegations Against MoonLake

The class action lawsuit's allegations stem from a belief that MoonLake misled investors regarding the superiority and efficacy of its drug candidate, SLK, particularly in relation to BIMZELX, an FDA-approved drug. The complaint points out several critical issues in the company's disclosures during the class period:

1. Misrepresentation of Drug Characteristics: The lawsuit alleges that MoonLake failed to adequately distinguish the substantive differences between SLK and BIMZELX, both of which target similar inflammatory cytokines, IL-17A and IL-17F.
2. Claims of Superiority Unfounded: Robbins LLP argues that the distinct Nanobody structure of SLK does not provide a clinical benefit over traditional monoclonal antibodies like BIMZELX. Furthermore, they assert that the structure claimed to enhance tissue penetration does not guarantee improved clinical outcomes.
3. Failure to Meet Efficacy Expectations: A critical development occurred on September 28, 2025, when MoonLake publicly announced results from its Phase 3 VELA program. These results identified that SLK did not demonstrate competitive efficacy relative to BIMZELX. This announcement led to a drastic decline in MoonLake's share price, plummeting by 89.9% to close at $6.24 the following day.

Next Steps for Affected Investors

Investors who feel they have been impacted by this situation may wish to consider participation in the class action against MoonLake Immunotherapeutics. Those who are interested in acting as lead plaintiffs must file their paperwork with the court by December 15, 2025. Serving as a lead plaintiff enables individuals to represent the class and guide the litigation process. However, it's crucial to note that it is not mandatory to participate in the lawsuit to qualify for a potential recovery; investors can remain as absent class members if they choose not to act.

Robbins LLP operates on a contingency fee basis, meaning that shareholders will incur no fees or expenses unless a recovery is achieved.

About Robbins LLP

Robbins LLP has been a recognized leader in shareholder rights litigation since its inception in 2002. The firm is committed to assisting shareholders in reclaiming losses and improving corporate governance practices while holding executives accountable for any wrongdoing.

For ongoing updates regarding this class action or to be notified of any settlements against MoonLake Immunotherapeutics, investors are encouraged to sign up for Stock Watch. This service offers alerts and essential information about corporate malfeasance.

As this legal situation unfolds, investors will be closely monitoring developments to see how MoonLake Immunotherapeutics responds to these serious allegations and the implications they may have on the company's future direction.

Attorney Advertising: Past results do not guarantee a similar outcome.